Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer
signature that identifies an IE patient subgroup with poor survival, representing those most likely to benefit from the "Gemcitabine-Nivolumab-SAHA" triple-combination therapy.
Authors
- Jiaoshun Chen
- Chunbin Zhu (ORCID: https://orcid.org/0009-0008-9580-6600)
- Rong Tang
- Dingru Li
- Y. B. Li
- Junyi Xu
- Zifeng Zhang (ORCID: https://orcid.org/0000-0001-7457-219X)
- Zehua Wang (ORCID: https://orcid.org/0009-0007-2803-9942)
- Miaoyan Wei
- Liquan Jin
- S. Y. Shi
- Yueyue Chen
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Shanghai Cancer Institute (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Advanced Science
- Published
- 2026-04-13
- DOI
- https://doi.org/10.1002/advs.202521844
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality